PHASE 1/2 RESPECT-GBM TRIAL OF RHENIUM (186RE) OBISBEMEDA IN RECURRENT GLIOBLASTOMA: SAFETY AND EFFICACY FROM THE PHASE 1 AND UPDATE ON PHASE 2

Authors
Category Primary study
Conference7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies, WFNOS and 30th Society for Neuro-Oncology Annual Meeting, SNO
Year 2025
This article has no abstract
Epistemonikos ID: dc01d7a0e8d32afe4b5005fff8bbe0bda7d88924
First added on: Dec 09, 2025